A synthetic monoketone analog of curcumin, termed 3, 5-bis (2-flurobenzylidene) piperidin-4-one (EF24), has been reported to inhibit the growth of a variety of cancer cells both in vitro and in vivo. However, whether EF24 has anticancer effects on cholangiocarcinoma (CCA) cells and the mechanisms remain to be investigated. The aim of our study was to evaluate the molecular mechanisms underlying the anticancer effects of EF24 on CCA tumor growth and metastasis. Cell proliferation, apoptosis, migration, invasion, tumorigenesis and metastasis were examined. EF24 exhibited time- and dose-dependent inhibitory effects on HuCCT-1, TFK-1 and HuH28 human CCA cell lines. EF24 inhibited CCA cell proliferation, migration, and induced G2/M phase arrest....
Caffeic acid phenethyl ester (CAPE) inhibits the growth of tumor cells and is a known inhibitor of n...
Abstract Background The Fanconi anemia (FA) pathway is a multigene DNA damage response network impli...
XL184 is a small-molecule kinase inhibitor recently included in first-line systemic therapy for pati...
The synthetic compound 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24) is a potent analog of curcu...
The synthetic compound 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24) is a potent analog of curcu...
EF24, a synthetic monocarbonyl analog of curcumin, shows significant potential as an anticancer agen...
EF24 is a curcumin analog that has improved anticancer activity over curcumin, but its therapeutic p...
<div><p>EF24 is a curcumin analog that has improved anticancer activity over curcumin, but its thera...
Diphenyl difluoroketone (EF24), a molecule having structural similarity to curcumin, was recently re...
<p>(<b>A</b>). The topological structures of curcumin (diferuloylmethane) and EF24 (diphenyl difluor...
In 2011, American Cancer Society reported that about 230,000 women were diagnosed with breast cancer...
Background: Pancreatic cancer is one of the most lethal of human malignancies known to date and show...
Abstract Background The role of Diphenyldifluoroketone (EF24), a synthetic analogue of curcumin with...
Purpose: In order to elucidate anticancer effects of monocarbonyl analogs of curcumin (MACs), we hav...
Up-regulation and association of nuclear factor kappa B (NF-κB) with carcinogenesis and tumor progre...
Caffeic acid phenethyl ester (CAPE) inhibits the growth of tumor cells and is a known inhibitor of n...
Abstract Background The Fanconi anemia (FA) pathway is a multigene DNA damage response network impli...
XL184 is a small-molecule kinase inhibitor recently included in first-line systemic therapy for pati...
The synthetic compound 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24) is a potent analog of curcu...
The synthetic compound 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24) is a potent analog of curcu...
EF24, a synthetic monocarbonyl analog of curcumin, shows significant potential as an anticancer agen...
EF24 is a curcumin analog that has improved anticancer activity over curcumin, but its therapeutic p...
<div><p>EF24 is a curcumin analog that has improved anticancer activity over curcumin, but its thera...
Diphenyl difluoroketone (EF24), a molecule having structural similarity to curcumin, was recently re...
<p>(<b>A</b>). The topological structures of curcumin (diferuloylmethane) and EF24 (diphenyl difluor...
In 2011, American Cancer Society reported that about 230,000 women were diagnosed with breast cancer...
Background: Pancreatic cancer is one of the most lethal of human malignancies known to date and show...
Abstract Background The role of Diphenyldifluoroketone (EF24), a synthetic analogue of curcumin with...
Purpose: In order to elucidate anticancer effects of monocarbonyl analogs of curcumin (MACs), we hav...
Up-regulation and association of nuclear factor kappa B (NF-κB) with carcinogenesis and tumor progre...
Caffeic acid phenethyl ester (CAPE) inhibits the growth of tumor cells and is a known inhibitor of n...
Abstract Background The Fanconi anemia (FA) pathway is a multigene DNA damage response network impli...
XL184 is a small-molecule kinase inhibitor recently included in first-line systemic therapy for pati...